Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.

Konstantinos PapamichaelRavy K VajraveluMark T OstermanAdam S Cheifetz

Published in: Digestive diseases and sciences (2018)

In real-life clinical practice, optimization of infliximab therapy can prevent drug discontinuation in approximately 3/4 of patients with ATI, especially in those with low titers. Large prospective studies are needed to confirm these data.

Keyphrases

patients with inflammatory bowel disease
clinical practice
ulcerative colitis
electronic health record
big data
case control
stem cells
mesenchymal stem cells
cell therapy